UM Programme Lead, Dr Sarah Welsh, presented the translational results to the successful NAVIVA trial at the AUA's Annual Meeting last week. See the full talk below.
‘NAXIVA’ stands for Neoadjuvant study of AXItinib for reducing extent of venous tumour thrombus in clear cell renal cell cancer with Venous invAsion, a phase II feasibility study investigating the effectiveness of the drug axitinib at reducing the extent of cancer invasion into the large blood vessels draining the kidney. To find out more about the trial, click here.
Dr Sarah Welsh thanks the patients and their families for participating in NAXIVA.
Comments